Syndax Pharmaceuticals (SNDX) Retained Earnings (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Retained Earnings of -$1.5 billion for Q1 2026, down 18.63% year-over-year from -$1.9 billion in Q1 2025, and down 2.83% quarter-over-quarter from -$1.5 billion in Q4 2025.
Syndax Pharmaceuticals (SNDX) Retained Earnings (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 18.63% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 18.63% YoY), while the FY2025 annual figure was -$1.5 billion, down 23.37% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.5 billion, down from -$1.5 billion in the prior quarter.
- The five-year high for Retained Earnings was -$580.9 million in Q1 2022, with the low at -$1.5 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$974.8 million (2024), against an average of -$1.0 billion.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings climbed 2.6% in 2022, then slumped 35.79% in 2024.
- Syndax Pharmaceuticals' Retained Earnings stood at -$693.0 million in 2022, then tumbled by 30.21% to -$902.4 million in 2023, then sank by 35.32% to -$1.2 billion in 2024, then declined by 23.37% to -$1.5 billion in 2025, then fell by 2.83% to -$1.5 billion in 2026.
- Business Quant data shows SNDX's Retained Earnings at -$1.5 billion in Q1 2026, -$1.5 billion in Q4 2025, and -$1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | -1.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.60 Bn |
| Mar 31, 2026 | -1.55 Bn |
| Dec 31, 2025 | -1.51 Bn |
| Sep 30, 2025 | -1.44 Bn |
| Jun 30, 2025 | -1.38 Bn |
| Mar 31, 2025 | -1.31 Bn |
| Dec 31, 2024 | -1.22 Bn |
| Sep 30, 2024 | -1.13 Bn |
| Jun 30, 2024 | -1.04 Bn |
| Mar 31, 2024 | -974.80 Mn |
| Dec 31, 2023 | -902.40 Mn |
| Sep 30, 2023 | -829.93 Mn |
| Jun 30, 2023 | -778.78 Mn |
| Mar 31, 2023 | -734.17 Mn |
| Dec 31, 2022 | -693.04 Mn |
| Sep 30, 2022 | -653.85 Mn |
| Jun 30, 2022 | -618.44 Mn |
| Mar 31, 2022 | -580.87 Mn |
| Dec 31, 2021 | -543.70 Mn |
| Sep 30, 2021 | -639.90 Mn |